The CDMOs DPT Laboratories and Confab will integrate under the leadership of Paul Johnson, group president and COO.
The CDMOs DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, have integrated under the leadership of Paul Johnson, group president and COO. Both DPT and Confab are owned by Renaissance Acquisition Holdings, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.
The integration includes a rebranding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s sales and marketing team to introduce Confab’s experts in complex solid, semi-solid, and liquid dosage forms to new pharmaceutical industry clients, especially in the US market. The management teams for both companies will remain inplace, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson. DPT has additional R&D and manufacturing facilities in Lakewood, New Jersey.
Source: DPT Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.